09 224 61 11

Lettergrootte: a a a

Wetenschappelijke publicaties

Tournoy K et al. (2018). Does nivolumab for progressed metastatic lung cancer fulfill its promises? An efficacy and safety analysis in 20 general hospitals. Lung Cancer; 115:49-55.

Marth C et al. (2017). ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer. Eur J Cancer.; 70:111-121.

Kaufman PA et al. (2015). Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane. J. Clin. Oncol.; 33(6):594-601.

Du Bois A et al. (2014). Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer. J. Clin. Oncol.; 32(30):3374-82.

Ryan CJ et al. (2013). Serum Androgens As Prognostic Biomarkers in Castration-Resistant Prostate Cancer: Results From an Analysis of a Randomized Phase III Trial. J. Clin. Oncol.; 31(22):2791-8.

Schmoll HJ et al. (2012). Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON III). J. Clin. Oncol.; 30(29):3588-95.

Scher HI et al. (2012). Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy. N. Engl. J. Med.; 367(13):1187-97.

Chinot OL et al. (2011). AVAglio: Phase 3 Trial of Bevacizumab Plus Temozolomide and Radiotherapy in Newly Diagnosed Glioblastoma Multiforme. Adv. Ther; 28(4):334-40.

Van Cutsem E et al. (2011). Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status. J. Clin. Oncol.; 29(15):2011-9.

de Bono JS et al. (2011). Abiraterone and Increased Survival in Metastatic Prostate Cancer. N. Engl. J. Med.; 364(21):1995-2005.

Sutherland S et al. (2010). Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases – the UK experience. Br. J. Cancer; 102(6):995-1002.

Stopeck AT et al. (2010). Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study. J. Clin. Oncol.; 28(35):5132-9.

Reed S et al. (2009). Cost Effectiveness of Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment. J. Clin. Oncol.; 27(13):2185-91.

Neyns B et al. (2009). Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma. Ann. Oncol.; 20(9):1596-603.